<DOC>
	<DOCNO>NCT00935012</DOCNO>
	<brief_summary>Open-label Safety Efficacy Evaluation Fx-1006a Patients V122i Or Wild-type Transthyretin ( ttr ) Amyloid Cardiomyopathy . Patients successfully complete Fx1B-201 report clinical unit Day 0 sign inform consent form determine eligibility Protocol Fx1B-303 . In addition , Day 0 , patient entrance criterion review , medical history demographic characteristic obtain . The physical examination ( include weight vital sign ) relevant end study clinical laboratory test ( alkaline phosphatase , alanine aminotransferase , aspartate aminotransferase , blood urea nitrogen , gamma glutamyl transferase , creatinine , total bilirubin , international normalize ratio , troponin I , troponin T , amino-terminal B-type natriuretic peptide ) Protocol Fx1B-201 use Protocol Fx1B-303 . If 30 day elapse final study visit Protocol Fx1B-201 Day 0 Protocol Fx1B-303 , abbreviate physical examination ( include weight vital sign ) clinical laboratory assessment must perform Day 0 . Eligible patient begin once-daily dose 20 mg Fx-1006A home Day 1 ( i.e. , first dose ) return clinical unit study visit every 6 month . Adverse event ( AEs ) concomitant medication use collect 6-month visit clinical unit . Blood draw clinical safety laboratory test abbreviate physical examination ( include weight vital sign ) also perform 6-month clinic visit . ECGs perform every 12 month annual basis . A telephone call make 3-month interval clinic visit assess safety use concomitant medication . For evaluation efficacy , Patient Global Assessment , NYHA classification , KCCQ , 6-minute walk test , efficacy-related clinical laboratory test ( serum level troponin T , troponin I , NT-pro-BNP ) determine every 6 month . In addition , echocardiogram perform every 12 month annual basis . An end study visit include safety efficacy assessment occur upon patient completion study , premature withdrawal ( reason ) , event program discontinuation Sponsor .</brief_summary>
	<brief_title>Safety And Efficacy Evaluation Of Fx-1006a In Patients With V122i Or Wild-Type Transthyretin ( TTR ) Amyloid Cardiomyopathy</brief_title>
	<detailed_description />
	<mesh_term>Cardiomyopathies</mesh_term>
	<criteria>Patient successfully complete Protocol Fx1B201 . If female ; patient post menopausal . If male , female partner postmenopausal . If female child bear potential , willing use acceptable method birth control 3 month last dose ( included female partner male participant ) . Patient willing comply protocol . Patient successfully complete Fx1B201 . Chronic use NSAIDS . Patient clinically significant medication condition increase risk study participation . Patient receive heart liver transplant .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>